SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
90
|
CROI Program Committee Chair Welcome to Wednesday
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
Successes in HIV-1 Vaccine Design: Accelerating Completion of One of Science's Most Difficult Vaccines (ABSTRACT
34)
Kevin O. Saunders
Duke Human Vaccine Institute, Durham, NC, USA
Tuberculosis in Children and Adolescents: From Neglect to Action (ABSTRACT
35)
Anneke C. Hesseling
Stellenbosch University, Cape Town, South Africa
Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable InSTI (ABSTRACT
174)
Samir Gupta
Indiana University Health, Indianapolis, IN, USA
Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing (ABSTRACT
175)
Nilay Thakkar
GSK plc, Collegeville, PA, USA
Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184 (ABSTRACT
176)
Hyunmoon Back
GSK plc, Collegeville, PA, USA
DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study (ABSTRACT
177)
Juergen K. Rockstroh
Bonn University Hospital, Bonn, Germany
Questions and Answers (Part 1)
Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study (ABSTRACT
178)
Charlotte-Paige Rolle
Orlando Immunology Center, Orlando, FL, USA
Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial (ABSTRACT
179)
Trevor A. Crowell
Henry M Jackson Foundation, Bethesda, MD, USA
Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks (ABSTRACT
180)
Pablo Tebas
University of Pennsylvania, Philadelphia, PA, USA
Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1 (ABSTRACT
181)
Chloe M. Orkin
Queen Mary University of London, London, UK
Questions and Answers (Part 2)
HIV Testing and Treatment Gaps in Subgroups of Men With HIV: Insights From 7 African countries (ABSTRACT
182)
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
Impact of Person-Centered Care Intervention on HIV Treatment Failure Response in Zambia (ABSTRACT
183)
Kombatende Sikombe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
The START mHealth Application Reduces Risk of Virologic Rebound in Men With HIV Who Use Stimulants (ABSTRACT
184)
Adam W. Carrico
Florida International University, Miami, FL, USA
Effects of a Coping Intervention on Viral Load Among South African Women With HIV and Sexual Trauma (ABSTRACT
185)
Kathleen J. Sikkema
Columbia University, New York, NY, USA
Questions and Answers (Part 1)
SMART ART: A Randomized Clinical Trial of Adaptive Strategies for HIV Viral Suppression in S Africa (ABSTRACT
186)
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
Early Findings From Cabotegravir Injectable HIV PrEP Rollout in Malawi: Uptake and Continuation (ABSTRACT
187)
Deborah Hoege
Georgetown University, Washington, DC, USA
Randomised Pilot of Pharmacy-Based Collection of PrEP Refills Among Female Sex Workers in Zimbabwe (ABSTRACT
188)
Constancia C. Watadzaushe
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
Integrating HIV and Hypertension Care Improves Blood Pressure in Uganda: A Cluster Randomized Trial (ABSTRACT
189)
Chris T. Longenecker
University of Washington, Seattle, WA, USA
Questions and Answers (Part 2)
Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV (ABSTRACT
166)
Boris Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure (ABSTRACT
167)
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention (ABSTRACT
168)
John K. Bui
Fred Hutchinson Cancer Center, Seattle, WA, USA
Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials (ABSTRACT
169)
Jiajie Li
University of Pennsylvania, Philadelphia, PA, USA
Questions and Answers (Part 1)
Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers (ABSTRACT
170)
Anna Farrell-Sherman
Fred Hutchinson Cancer Center, Seattle, WA, USA
A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure (ABSTRACT
171)
Gaurav Gaiha
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART (ABSTRACT
172)
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART (ABSTRACT
173)
Mirko Paiardini
Emory University, Atlanta, GA, USA
Questions and Answers (Part 2)
Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25 (ABSTRACT
190)
Chase A. Cannon
University of Washington, Seattle, WA, USA
HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study (ABSTRACT
191)
Melissa Schnure
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico (ABSTRACT
192)
Sari L. Reisner
University of Michigan, Ann Arbor, MI, USA
Awareness of Sex Partners’ HIV Status and Risk of HIV Acquisition: Rakai, Uganda (ABSTRACT
193)
Victor Ssempijja
Leidos Biomedical Research, Inc, Frederick, MD, USA
Questions and Answers (Part 1)
Comparative Effectiveness of 3 Benzathine Penicillin G-Based Regimens in PWH With Early Syphilis (ABSTRACT
194)
Kai Hsiang Chen
National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan
Early Syphilis and HIV Among Adolescents: United States, 20142-023 (ABSTRACT
195)
Daniel Gore
Centers for Disease Control and Prevention, Atlanta, GA, USA
Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial (ABSTRACT
196)
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
Meningococcal B (4CMenB) Vaccination for the Prevention of Gonorrhea in Men Who Have Sex With Men (ABSTRACT
197)
Kate L. Seib
Griffith University, Southport, Australia
Questions and Answers (Part 2)
Session Overview
Claude A. Mellins
Columbia University Irving Medical Center, New York, NY, USA
Depression, Anxiety, and Viral Suppression Among Adolescents and Young Adults in 9 African Countries (ABSTRACT
871)
Jiayu Wang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Implementation of a Mental Health Intervention for Youth With HIV in Kenya (ABSTRACT
872)
Pamela Kohler
University of Washington, Seattle, WA, USA
Primary Outcomes of SYV (Voice of Youth) Mental Health Intervention: A Randomized Trial in Tanzania (ABSTRACT
874)
Dorothy Dow
Duke University Medical Center, Durham, NC, USA
Primary Findings of IMPAACT 2016: A RCT of a Youth-Led Mental Health Intervention for Youth With HIV (ABSTRACT
873)
Geri Donenberg
University of Illinois at Chicago Center for Dissemination and Implementation Science, Chicago, IL, USA
Discussion With Audience Questions and Answers
Session Overview
Nicole A. Doria-Rose
Vaccine Research Center, Bethesda, MD, USA
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
90
|
